GOLDEN THROAT HOLDINGS GROUP COMPANY LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.75 HKD | +0.27% |
|
+1.63% | +11.94% |
| Sales 2021 | 821M 113M 886M 9.07B | Sales 2022 | 992M 137M 1.07B 10.96B | Capitalization | 1.25B 172M 1.35B 13.78B |
|---|---|---|---|---|---|
| Net income 2021 | 188M 25.95M 203M 2.08B | Net income 2022 | 281M 38.78M 304M 3.11B | EV / Sales 2021 | 0.47 x |
| Net cash position 2021 | 568M 78.37M 613M 6.28B | Net cash position 2022 | 653M 90.11M 705M 7.22B | EV / Sales 2022 | 0.6 x |
| P/E ratio 2021 |
5.07
x | P/E ratio 2022 |
4.43
x | Employees | 869 |
| Yield 2021 |
11.4% | Yield 2022 |
18.9% | Free-Float | 30.2% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.27% | ||
| 1 week | +1.63% | ||
| Current month | +4.17% | ||
| 1 month | -3.85% | ||
| 3 months | +10.95% | ||
| 6 months | +44.23% | ||
| Current year | +11.94% |
1 week
3.69
3.78
1 month
3.603.96
Current year
3.154.09
1 year
2.434.09
3 years
1.354.09
5 years
1.104.09
10 years
0.928.47
| Managers | Title | Age | Since |
|---|---|---|---|
Yong Zeng
CEO | Chief Executive Officer | 51 | 09/02/15 |
Qiang Cheng
DFI | Director of Finance/CFO | 55 | 31/05/18 |
Jin Qiang He
BRD | Director/Board Member | 55 | 09/02/15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jie Rong Zhu
BRD | Director/Board Member | 76 | 09/02/15 |
Yi Qun Cheng
BRD | Director/Board Member | 54 | 09/02/15 |
Hua Li
BRD | Director/Board Member | 54 | 09/02/15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 3.75 | +0.27% | 42,000 |
| 25/04/24 | 3.74 | -0.80% | 88,500 |
| 24/04/24 | 3.77 | +0.53% | 49,000 |
| 23/04/24 | 3.75 | -0.27% | 16,500 |
| 22/04/24 | 3.76 | +1.90% | 150,000 |
Delayed Quote Hong Kong S.E., April 26, 2024 at 09:08 am
More quotes
Golden Throat Holdings Group Company Limited is principally engaged in the manufacture and sales of pharmaceutical, healthcare food and other products. The Companyâs flagship product is Golden Throat Lozenges (OTC), which is a type of lozenge mainly designed to relieve symptoms of sore, dry throat and hoarse voice caused by acute pharyngitis. The Company's subsidiaries include Golden Throat Industrial Holdings Limited, Guangxi Golden Throat Investment Consulting Co., Ltd. and Guangxi Golden Throat Co., Ltd..
Sector
Pharmaceuticals
Calendar
21/08/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +11.94% | 354M | |
| +19.62% | 43.34B | |
| +20.44% | 21.96B | |
| +10.86% | 14.09B | |
| +13.07% | 13.64B | |
| +37.46% | 11.43B | |
| -8.59% | 6.86B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.22B |
- Stock Market
- Equities
- 6896 Stock
